Technology will be the Force Multiplier for Health Delivery
Dr Prathap C Reddy, the most respectable name in Indian healthcare talks heart to heart with eHEALTH magazine about his […]
Dr Prathap C Reddy, the most respectable name in Indian healthcare talks heart to heart with eHEALTH magazine about his […]
A leader, who is determined to bring about positive changes in Indias healthcare scenario, Rajendra Gupta has done a lot […]
Krishan Guptaa MD & Global CEO, ORGANIC INDIA Pvt Ltd Krishan Guptaa, Managing Director and Global Chief utive Officer (CEO) […]
Pfizer is conducting what it calls the first-ever all-electronic drug trial, in which patients at home will report outcomes to the company through the Internet.
Aurbindo pharma looses 0.91 percent stakes possessed by HSBC Global Investment Funds (Mauritius) Ltd in the open market sales.
Pfizer loses $10-billion-a-year revenue in November this year as its major cholesterol drug Lipitor patent expires.
Pfizer considers outsourcing manufacturing to India, ChinaUS-based pharmaceutical giant, Pfizer, is looking to cut costs by outsourcing as much as […]
The world’s top drug maker Pfizer said that it has entered into a deal to sell drug maker Biocon Ltd’s biosimilar versions of diabetes treatment insulin.
A website, Sharecare.com, is all set to provide platform to provide consumers with what they want to know on health and wellness subjects, reports New York Times.
Voxiva a global leader in mobile health information services, has announced the launch of text4baby, the first free mobile health service in the United States.
DNA Electronics Ltd, a developer of disposable, real-time gene testing at the point-of-care, has been named as the winner of the prestigious R&D prize at the Elektra09 European Electronics Industry Awards.
Indian pharmaceutical companies are reworking their strategies for Europe to cope with the intense pressure on drug prices because of changing trends in the key market.
In a move that would prevent MNCs such as GlaxoSmithKline (GSK), Eli Lilly, Roche and Pfizer from selling their drugs at a huge premium in India, the government may soon finalise norms for monitoring prices of costly imported patented medicines for diseases such as diabetes, arthritis, obesity, cancer and heart diseases.